



Landscape Samples

Fall 2025

Sample BizDash landscape visualizations for COVID-19 Vaccines, Merkel Cell Carcinoma, and Cardiovascular Drugs for Alzheimer's

About BizDash

BizDash is a new service offering fast creation of drug and clinical trial landscapes -- including powerful visualizations like pipeline bullseyes -- integrating data from key pipeline and trial databases.

Using industry-leading BizInt Smart Charts, Smart Data Integrator, and VantagePoint analytics algorithms, we leverage your valuable subscriptions for leading data sources including Adis, Citeline, Cortellis, GlobalData, and PatSnap to construct targeted visualizations and reports in PowerPoint, Excel and Word.

Contact us at: bizdash@bizint.com

How Does BizDash work?



Leveraging your subscriptions, we collect data on your landscape topic from the leading pipeline databases.

- GlobalData - Pipeline
- AdisInsight - Drugs
- Cortellis - Competitive Intelligence, Drug Discovery Intelligence
- Citeline - Pharmaprojects
- PatSnap - Synapse

BizDash analysts use industry-leading algorithms to process, integrate, and visualize the data.

- Combine search results and map columns with similar data.
- Identify related drug records across databases.
- Evaluate discrepancies and integrate data.
- Clean up, analyze, and visualize integrated data.
- Export drug landscapes to PowerPoint, Word, Excel, and BizDash Viewer.

You receive high-quality drug landscapes to inform your CI analysis.

- PowerPoint slides with visualizations and search strategy:
 - Bullseyes and Piano Charts (editable in PowerPoint)
 - Bubble Charts and Word Clouds (images in PowerPoint)
- Tabular reports with full integrated data, in Excel, Word, and BizDash Viewer.

Sample landscape topics


- [Covid-19 Vaccines](#)
- [Merkel Cell Carcinoma](#)
- [CVD Drugs for Alzheimer's](#)
- [Company pipeline - Amgen](#)

Covid-19 Vaccines

About this Landscape

Sources: AdisInsight, Citeline Pharmaprojects, Clarivate Cortellis.

Retrieval Date: 6/1/2021




Merkel Cell Carcinoma

About this Landscape

Sources: AdisInsight, Citeline Pharmaprojects, and Clarivate Cortellis.

Retrieval Date: 9/3/2017




CVD Drugs for Alzheimer's

About this Landscape

Sources: Citeline Pharmaprojects, GlobalData and Patsnap Synapse.

Retrieval Date: 2/2025




Company Pipeline - Amgen

About this Landscape

Sources: AdisInsight Drugs, Citeline Pharmaprojects, Cortellis, and GlobalData

Retrieval Date: 8/2022




Covid-19 Vaccines

About this Landscape


Sources: AdisInsight, Citeline Pharmaprojects, Clarivate Cortellis.

Retrieval Date: 6/1/2021


COVID-19 Vaccines – US, UK, & Europe



COVID-19 Vaccines – US, UK, & Europe



COVID-19 Vaccines – Rest of World





COVID-19 Vaccines – US, UK, & Europe

DNA	Inactivated	Live-attenuated	modified Antigen-Presenting Cell (APC)	Protein subunit	RNA	Viral vector	Virus-like particle
CORVax <i>OncoSec</i>	MIVAC <i>Milad</i>	COVI-VAC <i>Codagenix</i>	AV-COVID-19 <i>Aivita</i>	CoVax-1 <i>Univ Hosp Tuebingen</i>	mRNA 1283 <i>Moderna</i>	AdCOVID <i>Altimune</i>	VLP vaccine <i>Medicago</i>
COVIDeVax <i>Takis/Rottapharm</i>	VLA2001 <i>Valneva</i>			COVAX 19 <i>GeneCure</i>	mRNA vaccine <i>GSK/CureVac</i>	COH04S1 <i>City of Hope</i>	
INO 4800 <i>Inovio</i>				CoVepiT <i>OSE</i>	SAMLNPS <i>Gritstone</i>	MV-014212 <i>Meissa</i>	
				SPFN_1B-06-PL <i>US Army</i>	saRNA vaccine <i>Imperial Coll London</i>	VXA-CoV2-1 <i>Vaxart</i>	
				ABNCoV2 <i>AdaptVac</i>	ARCT-021 <i>Arcturus</i>	Ad5 COVID-19 <i>ImmunityBio</i>	
				AKS-452 <i>Akston</i>	mRNA-1273.351 <i>Moderna</i>	NasoVAX <i>Altimune</i>	
				KBP-COVID-19 <i>Kentucky BioProcessing</i>	MRT5500 <i>Translate/Sanofi</i>	GRAd-COV2 <i>ReiThera</i>	
				SCB 2019 <i>Clover/GSK</i>	CVnCoV <i>CureVac</i>	Sputnik V <i>Gamaleya</i>	COVID-19 phase
				SP-0253 <i>Sanofi/GSK</i>	BNT 162 <i>BioNTech/Pfizer</i>	Ad26.COVS.S <i>J&J</i>	Phase 1
				Covovax <i>Novavax</i>	mRNA 1273 <i>Moderna</i>	AZD 1222 <i>AstraZeneca/Oxford</i>	Phase 2
							Phase 3
							In Review
							Authorized




COVID-19 Vaccines – US, UK, & Europe

DNA	Inactivated	Live-attenuated	modified Antigen-Presenting Cell (APC)	Protein subunit	RNA	Viral vector	Virus-like particle
CORVax <i>OncoSec</i>	MIVAC <i>Milad</i>	COVI-VAC <i>Codagenix</i>	AV-COVID-19 <i>Aivita</i>	CoVax-1 <i>Univ Hosp Tuebingen</i>	mRNA 1283 <i>Moderna</i>	AdCOVID <i>Altimune</i>	VLP vaccine <i>Medicago</i>
COVIDeVax <i>Takis/Rottapharm</i>	VLA2001 <i>Valneva</i>			COVAX 19 <i>GeneCure</i>	mRNA vaccine <i>GSK/CureVac</i>	COH04S1 <i>City of Hope</i>	
INO 4800 <i>Inovio</i>				CoVepiT <i>OSE</i>	SAMLNPS <i>Gritstone</i>	MV-014212 <i>Meissa</i>	
				SPFN_1B-06-PL <i>US Army</i>	saRNA vaccine <i>Imperial Coll London</i>	VXA-CoV2-1 <i>Vaxart</i>	
				ABNCoV2 <i>AdaptVac</i>	ARCT-021 <i>Arcturus</i>	Ad5 COVID-19 <i>ImmunityBio</i>	
				AKS-452 <i>Akston</i>	mRNA-1273.351 <i>Moderna</i>	NasoVAX <i>Altimune</i>	
				KBP-COVID-19 <i>Kentucky BioProcessing</i>	MRT5500 <i>Translate/Sanofi</i>	GRAd-COV2 <i>ReiThera</i>	
				SCB 2019 <i>Clover/GSK</i>	CVnCoV <i>CureVac</i>	Sputnik V <i>Gamaleya</i>	
				SP-0253 <i>Sanofi/GSK</i>	BNT 162 <i>BioNTech/Pfizer</i>	Ad26.COVS.2.S <i>J&J</i>	
				Covovax <i>Novavax</i>	mRNA 1273 <i>Moderna</i>	AZD 1222 <i>AstraZeneca/Oxford</i>	
							COVID-19 phase
							Phase 1
							Phase 2
							Phase 3
							In Review
							Authorized



COVID-19 Vaccines – US, UK, & Europe





COVID-19 Vaccines – All Regions




Merkel Cell Carcinoma

About this Landscape

Sources: AdisInsight, Citeline
Pharmaprojects, and Clarivate Cortellis.

Retrieval Date: 9/3/2017


Merkel Cell Carcinoma Landscape






Merkel Cell Carcinoma Landscape

Phase 1
Phase 2
Phase 3
Launched



Status

- Launched for MCC
- MCC is a Lead indication
- Repurposed Launched drug
- MCC is a Secondary indication





Merkel Cell Carcinoma Landscape


Preclinical

Phase 1

Phase 2


Phase 3

Launched



Status

- Launched for MCC
- MCC is a Lead indication
- Repurposed Launched drug
- MCC is a Secondary indication





Merkel Cell Carcinoma Landscape

Preclinical	Phase 1	Phase 2	Launched
CK-301 <i>TG Therapeutics</i>	BGB-A317 <i>BeiGene</i>	PEN-221 <i>Tarveda Therapeutics</i>	Avelumab <i>Merck Group</i>
ETBX-061 <i>NantWorks</i>	utomilumab <i>MorphoSys</i>	Activated natural killer cells <i>ZelleRx</i>	
ETBX-051 <i>NantWorks</i>	Pasireotide <i>Novartis</i>	Tavokinogene telsaplasmid <i>Inovio</i>	
	SIRPa-Fc <i>Trillium Therapeutics</i>	nivolumab <i>Ono</i>	
	Glucopyranosyl lipid A <i>Immune Design</i>	Pembrolizumab <i>Merck & Co.</i>	
		ALT 803 <i>Altor, NantKwest</i>	
		F16 IL2 fusion protein <i>Philogen</i>	
		Cabozantinib <i>Exelixis</i>	
		pazopanib <i>GlaxoSmithKline</i>	
		Sapanisertib <i>Intellikine</i>	
		MCPyV TAG-specific polyclonal vaccine <i>Fred Hutchinson Cancer Res</i>	
		talimogene laherparepvec <i>Amgen</i>	

Drug Type

- Biological, other
- Cell/Gene therapy
- Monoclonal antibodies
- Protein/Peptide
- Small molecules
- Vaccine



Merkel Cell Carcinoma Landscape

Biological, other	Cell/Gene therapy	Monoclonal antibodies	Protein/Peptide	Small molecules	Vaccine
PEN-221 <i>Tarveda Therapeutics</i>	Activated natural killer cells <i>ZelleRx</i>	CK-301 <i>TG Therapeutics</i>	ETBX-061 <i>NantWorks</i>	Glucopyranosyl lipid A <i>Immune Design</i>	ETBX-051 <i>NantWorks</i>
	Tavokinogene telsaplasmid <i>Inovio</i>	BGB-A317 <i>BeiGene</i>	Pasireotide <i>Novartis</i>	Sapanisertib <i>Intellikine</i>	MCPyV TAg-specific polyclonal vaccine <i>Fred Hutchinson Cancer Res</i>
		utomilumab <i>MorphoSys</i>	SIRPa-Fc <i>Trillium Therapeutics</i>	Cabozantinib <i>Exelixis</i>	talimogene laherparepvec <i>Amgen</i>
		nivolumab <i>Ono</i>	ALT 803 <i>Altor BioScience, NantKwest</i>	pazopanib <i>GlaxoSmithKline</i>	Phase (Merkel cell carcinoma) Preclinical Phase 1 Phase 2 Marketed
		Pembrolizumab <i>Merck & Co</i>	F16 IL2 fusion protein <i>Philogen</i>		
		Avelumab <i>Merck Group</i>			



Merkel Cell Carcinoma Landscape

Biological, other	Cell/Gene therapy	Monoclonal antibodies	Protein/Peptide	Small molecules	Vaccine
PEN-221 <i>Tarveda Therapeutics</i> Lead	Activated natural killer cells <i>ZelleRx</i> Lead	CK-301 <i>TG Therapeutics</i> Lead	ETBX-061 <i>NantWorks</i> Lead	Glucopyranosyl lipid A <i>Immune Design</i> Secondary	ETBX-051 <i>NantWorks</i> Lead
	Tavokinogene telsaplasmid <i>Inovio</i> Lead	BGB-A317 <i>BeiGene</i> Secondary	Pasireotide <i>Novartis</i> Repurposed	Sapanisertib <i>Intellikine</i> Lead	MCPyV TAg-specific polyclonal vaccine <i>Fred Hutchinson Cancer Res</i> Lead
		utomilumab <i>MorphoSys</i>	SIRPa-Fc <i>Trillium Therapeutics</i> Lead	Cabozantinib <i>Exelixis</i> Repurposed	talimogene laherparepvec <i>Amgen</i> Repurposed
		nivolumab <i>Ono</i> Repurposed	ALT 803 <i>Altor BioScience, NantKwest</i> Lead	pazopanib <i>GlaxoSmithKline</i> Repurposed	Phase (Merkel cell carcinoma) Preclinical Phase 1 Phase 2 Marketed
		Pembrolizumab <i>Merck & Co.</i> Repurposed	F16 IL2 fusion protein <i>Philogen</i> Lead		
		Avelumab <i>Merck Group</i> Launched			

Merkel Cell Carcinoma Landscape

		Avelumab <i>Merck Group,</i>			Phase (Merkel cell carcinoma) Preclinical Phase 1 Phase 2 Marketed
		Pembrolizumab <i>Merck & Co.</i>	F16 IL2 fusion protein <i>Philogen</i>		
		nivolumab <i>Ono</i>	ALT 803 Altor BioScience, NantKwest	pazopanib <i>GlaxoSmithKline</i>	
		utomilumab <i>MorphoSys</i>	SIRPa-Fc <i>Trillium Therapeutics</i>	Cabozantinib <i>Exelixis</i>	
	Tavokinogene telsaplasmid <i>Inovio</i>	BGB-A317 <i>BeiGene</i>	Pasireotide <i>Novartis</i>	Sapanisertib <i>Intellikine</i>	MCPyV TAγ-specific polyclonal vaccine <i>Fred Hutchinson Cancer Res</i>
	PEN-221 <i>Tarveda Therapeutics</i>	Activated natural killer cells <i>ZelleRx</i>	CK-301 <i>TG Therapeutics</i>	ETBX-061 <i>NantWorks</i>	Glucopyranosyl lipid A <i>Immune Design</i>
					ETBX-051 <i>NantWorks</i>
Biological, other	Cell/Gene therapy	Monoclonal antibodies	Protein/Peptide	Small molecules	Vaccine




Merkel Cell Carcinoma Landscape

	Biological, other	Cell/Gene therapy	Monoclonal antibodies	Protein/Peptide	Small molecules	Vaccine
	PEN-221 <i>Tarveda Therapeutics</i>	Activated natural killer cells <i>ZelleRx</i>	CK-301 <i>TG Therapeutics</i>	ETBX-061 <i>NantWorks</i>	Glucopyranosyl lipid A <i>Immune Design</i>	ETBX-051 <i>NantWorks</i>
		Tavokinogene telpaplasmid <i>Inovio</i>	BGB-A317 <i>BeiGene</i>	Pasireotide <i>Novartis</i>	Sapanisertib <i>Intellikine</i>	MCPyV TAg-specific polyclonal vaccine <i>Fred Hutchinson Cancer Res</i>
Phase (Merkel cell carcinoma)			utomilumab <i>MorphoSys</i>	SIRPa-Fc <i>Trillium Therapeutics</i>	Cabozantinib <i>Exelixis</i>	talimogene laherparepvec <i>Amgen</i>
Preclinical						
Phase 1			nivolumab <i>Ono</i>	ALT 803 <i>Altor BioScience, NantKwest</i>	pazopanib <i>GlaxoSmithKline</i>	
Phase 1/2						
Phase 2			Pembrolizumab <i>Merck & Co</i>	F16 IL2 fusion protein <i>Philogen</i>		



Merkel Cell Carcinoma Landscape



CVD Drugs for Alzheimer's

About this Landscape

Sources: Citeline Phmaprojects, GlobalData and Patsnap Synapse.

Retrieval Date: 2/2025

Biologics for Alzheimer's and CVD			
Phase 1	Phase 2	Phase 3	Launched
Mivelsiran <i>Alnylam</i>	Allo-hMSCs <i>University of Miami</i>	semaglutide <i>Novo Nordisk</i>	cerebroprotein hydrolysate <i>Invision Medi Sciences</i>
NVG-291 <i>NervGen</i>	Iaromestrocel <i>Longeveron</i>		Fraction F <i>Gentium</i>
Zilebesiran <i>Alnylam</i>	TB-006 <i>TrueBinding</i>		
	Daratumumab <i>J&J</i>		
	liraglutide <i>Novo Nordisk</i>		
	sovateltide <i>Pharmazz</i>		
	aMBMC, CardioCell <i>CardioCell</i>		
	epoetin alfa <i>Center of Molecular Immunology</i>		
	foralumab <i>Tiziana</i>		
	Recombinant Albumin <i>ProTgen</i>		
			Alzheimer's vs other indications
			AD is a Lead indication
			Repurposed
			AD is a Secondary indication



Biologics for Alzheimer's and CVD

Phase 1	Phase 2	Phase 3	Launched
Mivelsiran <i>Alnylam</i>	Allo-hMSCs <i>University of Miami</i>	semaglutide <i>Novo Nordisk</i>	cerebroprotein hydrolysate <i>Invision Medi Sciences</i>
NVG-291 <i>NervGen</i>	Iaromestrocel <i>Longeveron</i>		Fraction F <i>Gentium</i>
Zilebesiran <i>Alnylam</i>	TB-006 <i>TrueBinding</i>		
	Daratumumab <i>J&J</i>		
	liraglutide <i>Novo Nordisk</i>		
	sovate tide <i>Pharmazz</i>		
	aMBMC, CardioCell <i>CardioCell</i>		
	epoetin alfa <i>Center of Molecular Immunology</i>		
	foralumab <i>Tiziana</i>		
	Recombinant Albumin <i>ProTgen</i>		
			Alzheimer's vs other indications
			AD is a Lead indication
			Repurposed
			AD is a Secondary indication



Biologics for Alzheimer's and CVD

Phase 1	Phase 2		Phase 3	Launched
Mivelsiran <i>Alnylam</i> Gene silencing	Allo-hMSCs <i>University of Miami</i> Cell therapy	sovateptide <i>Pharmazz</i> Peptide/Protein	semaglutide <i>Novo Nordisk</i> Peptide/Protein	cerebroprotein hydrolysate <i>Invision Medi Sciences</i> Peptide/Protein
NVG-291 <i>NervGen Pharma</i> Peptide/Protein	Iaromestrocel <i>Longeveron</i> Cell therapy	aMBMC, CardioCell <i>CardioCell</i> Cell therapy		Fraction F <i>Gentium</i> Biological, other
Zilebesiran <i>Alnylam</i> Gene silencing	TB-006 <i>TrueBinding</i> Monoclonal Antibody	epoetin alfa <i>Center of Molecular Immunology</i> Peptide/Protein		
	Daratumumab <i>J&J</i> Monoclonal Antibody	foralumab <i>Tiziana</i> Monoclonal Antibody		Alzheimer's vs other indications
	liraglutide <i>Novo Nordisk</i> Peptide/Protein	Recombinant Albumin <i>ProTgen</i> Peptide/Protein		AD is a Lead indication
				Repurposed
				AD is a Secondary indication



Drugs for Alzheimer's and CVD Drug type by status





Drugs for Alzheimer's and CVD – Indications




Company Pipeline - Amgen

About this Landscape


Sources: AdisInsight Drugs, Citeline
Pharmaprojects, Cortellis, and
GlobalData

Retrieval Date: 8/2022

Amgen clinical stage - drug type by status



Amgen clinical stage pipeline





Amgen Clinical Stage Pipeline

Phase 1		Phase 2	Phase 3
AMG 133	KITE796	acapatamab	bemarituzumab
AMG 199	AMG 224	AMB 051	brazikumab
AMG 340	AMG 256	AMG 729	eculizumab
AMG 509	AMG 609	BMS 986258	epratuzumab
AMG 910	FPT 155	Cabiralizumab	ganitumab
AMG 994	TNB-486	efavaleukin alfa	ustekinumab
AMG330	AMG 650	namilumab	aflibercept
AMG404	AMG 786	ordesikimab	
AMG427	BGE105	tarlatamab	
AZD 8630	CK-136	CDX 301	
CX 904		olpasiran	
FPA150		Rozibafusp alfa	
OBT-076		AMG 193	
pacanalotamab		AMG 319	
pasotuxizumab		AMG 634	
TNB 383B			
TNB-738			
XmAb-968			
AMG 119			
G-207			

Type of Compound

- Antibody
- Cell/Gene therapy
- Other Biologic
- Small molecule




Amgen Clinical Stage Pipeline

Antibody		Cell/Gene therapy	Other Biologic	Small molecule
AMG 133	AMG 729	AMG 119	AMG 224	AMG 650
AMG 199	BMS 986258	G-207	AMG 256	AMG 786
AMG 340	Cabiralizumab	KITE796	AMG 609	BGE105
AMG 509	efavaleukin alfa		FPT 155	CK-136
AMG 910	namilumab		TNB-486	AMG 193
AMG 994	ordesikimab		CDX 301	AMG 319
AMG330	tarlatamab		olpasiran	AMG 634
AMG404	bemarituzumab		Rozibafusp alfa	Highest Phase Phase 1 Phase 2 Phase 3
AMG427	brazikumab		aflibercept	
AZD 8630	eculizumab			
CX 904	epratuzumab			
FPA150	ganitumab			
OBT-076	ustekinumab			
pacanalotamab				
pasotuxizumab				
TNB 383B				
TNB-738				
XmAb-968				
acapatamab				
AMB 051				




Amgen clinical stage - drug type by status





Amgen preclinical through launch - drug type by status





Amgen Clinical Stage Pipeline – Mechanism of Action

Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 (B Cell Maturation Antigen or CD269 or BCMA or TNFRSF17)

Angiogenesis inhibitors

Immunostimulants

Immunomodulators

Tumour necrosis factor alpha antagonist

Antibody-dependent cell cytotoxicity

Immunologic cytotoxicity

Immunosuppressant

APRIL receptor modulator

CD3 modulator

Tubulin Inhibitor

Angiogenesis inhibitor

Immuno-oncology therapy

T cell stimulant

Immune checkpoint stimulant

Apoptosis stimulant

CRTH2 antagonist

Immunostimulant

Cyclin-dependent kinase-4 inhibitor

C-kit inhibitor

CD3 agonist

Apoptosis stimulants

Bradykinin B1 receptor antagonist

T lymphocyte stimulants

DNA Synthesis Inhibitor

T lymphocyte replacements

Immunosuppressants

VEGFR-2 tyrosine kinase inhibitor

Immune checkpoint inhibitor

Cytotoxic T lymphocyte stimulants

Interleukin 1 antagonist

Secretase beta inhibitor

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Inhibitor